Literature DB >> 19248684

MSH6 inactivation and emergent temozolomide resistance in human glioblastomas.

Daniel P Cahill1, Patrick J Codd, Tracy T Batchelor, William T Curry, David N Louis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19248684

Source DB:  PubMed          Journal:  Clin Neurosurg        ISSN： 0069-4827


× No keyword cloud information.
  18 in total

1.  Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth.

Authors:  Giovanni Germano; Simona Lamba; Giuseppe Rospo; Ludovic Barault; Alessandro Magrì; Federica Maione; Mariangela Russo; Giovanni Crisafulli; Alice Bartolini; Giulia Lerda; Giulia Siravegna; Benedetta Mussolin; Roberta Frapolli; Monica Montone; Federica Morano; Filippo de Braud; Nabil Amirouchene-Angelozzi; Silvia Marsoni; Maurizio D'Incalci; Armando Orlandi; Enrico Giraudo; Andrea Sartore-Bianchi; Salvatore Siena; Filippo Pietrantonio; Federica Di Nicolantonio; Alberto Bardelli
Journal:  Nature       Date:  2017-11-29       Impact factor: 49.962

2.  The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1-Mutant Cancers and Potentiates NAD+ Depletion-Mediated Cytotoxicity.

Authors:  Kensuke Tateishi; Fumi Higuchi; Julie J Miller; Mara V A Koerner; Nina Lelic; Ganesh M Shankar; Shota Tanaka; David E Fisher; Tracy T Batchelor; A John Iafrate; Hiroaki Wakimoto; Andrew S Chi; Daniel P Cahill
Journal:  Cancer Res       Date:  2017-06-16       Impact factor: 12.701

3.  Inhibition of EZH2 reverses chemotherapeutic drug TMZ chemosensitivity in glioblastoma.

Authors:  Tian-Yu Fan; Hai Wang; Peng Xiang; Ya-Wei Liu; He-Zhen Li; Bing-Xi Lei; Meng Yu; Song-Tao Qi
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

4.  Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype.

Authors:  Jian Teng; Seyedali Hejazi; Lotte Hiddingh; Litia Carvalho; Mark C de Gooijer; Hiroaki Wakimoto; Marco Barazas; Marie Tannous; Andrew S Chi; David P Noske; Pieter Wesseling; Thomas Wurdinger; Tracy T Batchelor; Bakhos A Tannous
Journal:  Neuro Oncol       Date:  2018-04-09       Impact factor: 12.300

5.  Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts.

Authors:  Gaspar J Kitange; Ann C Mladek; Brett L Carlson; Mark A Schroeder; Jenny L Pokorny; Ling Cen; Paul A Decker; Wenting Wu; Gwen A Lomberk; Shiv K Gupta; Raul A Urrutia; Jann N Sarkaria
Journal:  Clin Cancer Res       Date:  2012-06-06       Impact factor: 12.531

6.  Mechanism-based design of agents that selectively target drug-resistant glioma.

Authors:  Kingson Lin; Susan E Gueble; Ranjini K Sundaram; Eric D Huseman; Ranjit S Bindra; Seth B Herzon
Journal:  Science       Date:  2022-07-28       Impact factor: 63.714

7.  Association of MSH6 mutation with glioma susceptibility, drug resistance and progression.

Authors:  Chaoran Xie; Hansong Sheng; Nu Zhang; Shiting Li; Xiangyu Wei; Xuesheng Zheng
Journal:  Mol Clin Oncol       Date:  2016-05-20

8.  Retinoblastoma Binding Protein 4 Modulates Temozolomide Sensitivity in Glioblastoma by Regulating DNA Repair Proteins.

Authors:  Gaspar J Kitange; Ann C Mladek; Mark A Schroeder; Jenny C Pokorny; Brett L Carlson; Yuji Zhang; Asha A Nair; Jeong-Heon Lee; Huihuang Yan; Paul A Decker; Zhiguo Zhang; Jann N Sarkaria
Journal:  Cell Rep       Date:  2016-03-10       Impact factor: 9.423

9.  The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.

Authors:  Barbara Banelli; Elisa Carra; Federica Barbieri; Roberto Würth; Federica Parodi; Alessandra Pattarozzi; Roberta Carosio; Alessandra Forlani; Giorgio Allemanni; Daniela Marubbi; Tullio Florio; Antonio Daga; Massimo Romani
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

10.  Clonal analysis in recurrent astrocytic, oligoastrocytic and oligodendroglial tumors implicates IDH1- mutation as common tumor initiating event.

Authors:  Ulrike Lass; Astrid Nümann; Kajetan von Eckardstein; Jürgen Kiwit; Florian Stockhammer; Jörn A Horaczek; Julian Veelken; Christel Herold-Mende; Judith Jeuken; Andreas von Deimling; Wolf Mueller
Journal:  PLoS One       Date:  2012-07-23       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.